- Chemotherapy
- Immunotherapy
- Combination Therapies
- Others
Merkel Cell Carcinoma Treatment Market size was valued at USD 3.38 billion in 2022 and is poised to grow at a CAGR of 3.9% from 2023-29. Merkel cell carcinoma is an uncommon type of skin cancer and is also known as neuroendocrine skin carcinoma or trabecular carcinoma. It occurs due to the abnormal growth of Merkel cells. This cancer has grown and spreads rapidly beyond the skin. Merkel cells are the type of skin neuroendocrine cells as they share some features with hormone making and nerve cells. Merkel cells are found at the base of the epidermis, the top layer of the skin and are very close to nerve endings which helps us to sense touch and light. The report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the market report include suppliers, manufacturers, marketers, policymakers.
Merkel Cell Carcinoma Treatment Market Key Developments:
- In 2017 September, Merck KGaA and Pfizer Inc. received market authorization from European Commission for its BAVENCIO (avelumab) for the treatment of metastatic Merkel cell carcinoma.
- In March 2017, Merck KGaA and Pfizer Inc. received U.S.FDA approval for its BAVENCIO (avelumab) for the treatment of metastatic Merkel cell carcinoma.
Global Merkel Cell Carcinoma Treatment Market Summary
Study Period
2023-29
Base Year
2022
CAGR
3.9%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Merkel Cell Carcinoma Treatment Market Dynamics
Increasing cases of Merkel cell carcinoma and rising demand for immunotherapy treatment are major factors, expected to drive the growth of the market. Furthermore, growing investments in R&D, developing healthcare infrastructure, are the factors which are propelling the growth of Merkel cell carcinoma treatment market. However, lack of nursing care, adverse effects associated with chemo and immunotherapy drugs, high cost associated with the medicines, restricted adequacy of the medication and stringent regulatory framework are expected to hamper the growth of MCC treatment market.
North-America Got Significant Share of
Merkel Cell Carcinoma Treatment Market Regional
North America and Europe are expected to dominate the markets in global MCC treatment market by holding largest revenue share owing to the increased prevalence of MCC, increasing treatment options, growing pool of population and increased advancements in technologies, increase in initiation of medical campaigns, government and non-government initiations. Asia Pacific region and Latin America region is anticipated to have a lucrative growth rate during the forecast period due to increasing population pool, developing economic conditions coupled with rising prevalence of MCC.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Global Merkel Cell Carcinoma Treatment Market Segmentation
By Drugs
By Distribution Channel
- Hospitals
- Oncology research institutes
- Ambulatory surgical centers
- Retail Pharmacies
- Online Pharmacies
By Geography
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
Frequently Asked Questions
The merkel cell carcinoma treatment market size was valued at USD 3.38 billion in 2021
The merkel cell carcinoma treatment market key players are Pfizer (U.S) Amgen Inc.(U.S) Merck & Co. Inc.(U.S) BeiGene Ltd.(China) OncoSec Medical Inc.(U.S) Millennium Pharmaceuticals Inc.(U.S)
The merkel cell carcinoma treatment market segments are by drugs and distribution channel
| 1.Executive Summary |
| 2.Global Merkel Cell Carcinoma Treatment Market Introduction |
| 2.1.Global Merkel Cell Carcinoma Treatment Market - Taxonomy |
| 2.2.Global Merkel Cell Carcinoma Treatment Market - Definitions |
| 2.2.1.Drugs |
| 2.2.2.Distribution Channel |
| 2.2.3.Region |
| 3.Global Merkel Cell Carcinoma Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Merkel Cell Carcinoma Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Merkel Cell Carcinoma Treatment Market By Drugs, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Chemotherapy |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Immunotherapy |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Combination Therapies |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Others |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global Merkel Cell Carcinoma Treatment Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Hospitals |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Oncology research institutes |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Ambulatory surgical centers |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Retail Pharmacies |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Online Pharmacies |
| 6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7.Global Merkel Cell Carcinoma Treatment Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Merkel Cell Carcinoma Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. Drugs Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Chemotherapy |
| 8.1.2.Immunotherapy |
| 8.1.3.Combination Therapies |
| 8.1.4.Others |
| 8.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Hospitals |
| 8.2.2.Oncology research institutes |
| 8.2.3.Ambulatory surgical centers |
| 8.2.4.Retail Pharmacies |
| 8.2.5.Online Pharmacies |
| 8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Merkel Cell Carcinoma Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Chemotherapy |
| 9.1.2.Immunotherapy |
| 9.1.3.Combination Therapies |
| 9.1.4.Others |
| 9.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Hospitals |
| 9.2.2.Oncology research institutes |
| 9.2.3.Ambulatory surgical centers |
| 9.2.4.Retail Pharmacies |
| 9.2.5.Online Pharmacies |
| 9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 9.3.6.Rest of EU |
| 10.Asia Pacific (APAC) Merkel Cell Carcinoma Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Chemotherapy |
| 10.1.2.Immunotherapy |
| 10.1.3.Combination Therapies |
| 10.1.4.Others |
| 10.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hospitals |
| 10.2.2.Oncology research institutes |
| 10.2.3.Ambulatory surgical centers |
| 10.2.4.Retail Pharmacies |
| 10.2.5.Online Pharmacies |
| 10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Merkel Cell Carcinoma Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Chemotherapy |
| 11.1.2.Immunotherapy |
| 11.1.3.Combination Therapies |
| 11.1.4.Others |
| 11.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hospitals |
| 11.2.2.Oncology research institutes |
| 11.2.3.Ambulatory surgical centers |
| 11.2.4.Retail Pharmacies |
| 11.2.5.Online Pharmacies |
| 11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Merkel Cell Carcinoma Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Chemotherapy |
| 12.1.2.Immunotherapy |
| 12.1.3.Combination Therapies |
| 12.1.4.Others |
| 12.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hospitals |
| 12.2.2.Oncology research institutes |
| 12.2.3.Ambulatory surgical centers |
| 12.2.4.Retail Pharmacies |
| 12.2.5.Online Pharmacies |
| 12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Pfizer (U.S) |
| 13.2.2.Amgen Inc.(U.S) |
| 13.2.3.Merck & Co. Inc.(U.S) |
| 13.2.4.BeiGene Ltd.(China) |
| 13.2.5.OncoSec Medical Inc.(U.S) |
| 13.2.6.Millennium Pharmaceuticals Inc.(U.S) |
| 13.2.7.Oncovir Inc. (U.S) |
| 13.2.8.Novartis AG (Switzerland) |
| 13.2.9.NantKwest Inc. (U.S) |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
- Pfizer (U.S)
- Amgen Inc.(U.S)
- Merck & Co. Inc.(U.S)
- BeiGene Ltd.(China)
- OncoSec Medical Inc.(U.S)
- Millennium Pharmaceuticals Inc.(U.S)
- Oncovir Inc. (U.S)
- Novartis AG (Switzerland)
- NantKwest Inc. (U.S)